May 10, 2018 / 5:10 AM / 4 months ago

BRIEF-Genentech Phase III IMblaze370 Study Did Not Meet Primary Endpoint Compared To Regorafenib

May 10 (Reuters) -

* GENENTECH PROVIDES UPDATE ON PHASE III STUDY OF TECENTRIQ (ATEZOLIZUMAB) AND COTELLIC (COBIMETINIB) IN PEOPLE WITH HEAVILY PRE-TREATED LOCALLY ADVANCED OR METASTATIC COLORECTAL CANCER

* GENENTECH - PHASE III IMBLAZE370 STUDY EVALUATING COMBINATION OF TECENTRIQ AND COTELLIC DID NOT MEET PRIMARY ENDPOINT OF OVERALL SURVIVAL COMPARED TO REGORAFENIB

* GENENTECH- RESULTS FROM IMBLAZE370 SHOWED TREATMENT WITH TECENTRIQ ALONE DID NOT PROVIDE MEANINGFUL CLINICAL BENEFIT COMPARED TO REGORAFENIB Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below